Skip to main content
Delfa

← Trials/Trial dossier/NCT00018382

CompletedPhase 2

Insulin, Neurogenetics and Memory in Alzheimer's Disease

Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach

Asset

Rosiglitazone

Listed sites

1

Recruiting sites

-

Enrollment

-

Study population

Alzheimer’s disease

Key I/E criterion

•Age 55-80

Primary endpoint

-

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDAGCG-012-98S
NCT IDNCT00018382

Timeline

Milestones

Study start1999-10 (month precision)
Study first posted2001-07-05estimated
Study completion2003-03 (month precision)
Last update posted2009-01-21estimated

Assets

Drug assets

Rosiglitazone

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Eligibility criteria

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.